Biocon Biologics Ltd (BBL), a unit of Biocon Ltd (BIOCON), Thursday said that the U.S. Food and Drug Administration (FDA) has approved Jobevne, a biosimilar to Bevacizumab.
Bevacizumab, sold under the brand name Avastin in the U.S., is indicated to treat many types of cancers including colorectal cancer, non-small cell lung cancer, glioblastoma, among others.
The approval of Jobevne expands Biocon Biologics' biosimilar oncology portfolio in the U.S. which also includes Ogivri and Fulphila. The company also markets Bevacizumab in Europe and Canada under the name Abevmy, the company said in a statement.
In 2023, sales of bevacizumab were about $2 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.